Building the Next Generation of Respiratory and Infectious Disease Challenge Models
Dear Kenneth,
Respiratory viruses such as RSV and hMPV continue to challenge traditional clinical development. Seasonality, co-circulation, and variability often limit what field studies can reveal, particularly in early development.
As a result, controlled human infection models are increasingly being used to generate earlier, more predictive insights. This shift is reshaping how respiratory vaccines and antivirals are evaluated before larger trials begin. This article examines how experience with RSV challenge studies has informed the development of the hMPV model, and why this progression matters for the future of respiratory research.
The Article Examines:
- RSV challenge studies as a blueprint for hMPV
- Why hMPV has emerged as a priority respiratory target
- How challenge models support translation to field trials
- Design considerations for safe, reproducible respiratory studies
Download the article to explore how RSV and hMPV challenge models are advancing respiratory clinical research.
Don’t want to receive these emails? No problem, simply click on the Unsubscribe link below.
By accessing this content, you are permitting hVIVO or a third party to contact you regarding the content (by phone or email).